Mustang Bio shares are trading higher after the company on Monday announced safety and efficacy data from the complete Waldenstrom Macroglobulinemia cohort of its Phase 1/2 clinical trial of MB-106, showing an overall response rate of 90% with one patient remaining in complete remission at 31 months.
Portfolio Pulse from Benzinga Newsdesk
Mustang Bio shares are trading higher after the company announced positive safety and efficacy data from its Phase 1/2 clinical trial of MB-106, showing a 90% overall response rate and one patient in complete remission for 31 months.
June 18, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio shares are trading higher following the announcement of positive data from its Phase 1/2 clinical trial of MB-106, with a 90% overall response rate and one patient in complete remission for 31 months.
The positive clinical trial results indicate strong efficacy and safety of MB-106, which is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100